{"id":744989,"date":"2014-05-06T07:59:00","date_gmt":"2014-05-06T07:59:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/"},"modified":"2023-03-22T00:04:55","modified_gmt":"2023-03-22T04:04:55","slug":"merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/","title":{"rendered":"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&#038;D Focus; Drive Growth and Productivity"},"content":{"rendered":"<p class=\"bwalignc\">       Company Provides Updates on Near-Term Opportunities and        Immuno-Oncology Strategy     <\/p>\n<ul>\n<li>         Announced Sale of Consumer Care Business to Bayer AG for $14.2          Billion; Enters into Worldwide Collaboration with Bayer to Market and          Develop Novel Therapies for Cardiovascular Disease       <\/li>\n<li>         MK-3475 BLA Accepted for Priority Review by FDA; Company Announced          Plans to File in EU in 2014       <\/li>\n<li>         Provided Updates on Clinical Development Programs for Oncology,          Hepatitis C and HIV       <\/li>\n<li>         Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis          in Second Half of 2014       <\/li>\n<\/ul>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today is hosting an Investor Briefing at the company\u2019s research facility<br \/>\n      in Boston. The briefing is also available via webcast at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=9fa1647efde9fb28704ca25f28b8e538\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      starting at 9:00 a.m. EDT.\n    <\/p>\n<p>\n      Members of the company\u2019s senior management team provided updates on the<br \/>\n      progress Merck has made on its multi-year, strategic initiative to<br \/>\n      sharpen its commercial and research and development (R&amp;D) focus, bolster<br \/>\n      its innovative pipeline and accelerate efforts to redesign its operating<br \/>\n      model and reduce its cost base.\n    <\/p>\n<p>\n      <b>New, Focused Operating Model<\/b>\n    <\/p>\n<p>\n      Merck has implemented a focused, more agile operating model and a more<br \/>\n      flexible cost structure in order to drive growth and productivity for<br \/>\n      the long term. This has allowed the company to reduce costs, while at<br \/>\n      the same time take proactive steps to further sharpen its R&amp;D and<br \/>\n      commercial focus and bolster its innovative pipeline. This includes<br \/>\n      greater integration between the company\u2019s commercial and R&amp;D<br \/>\n      organizations and improved therapeutic, pipeline and market<br \/>\n      prioritization to focus on the best opportunities for growth.\n    <\/p>\n<p>\n      \u201cWe\u2019re focusing on improving our growth opportunities by investing in<br \/>\n      the right programs, products and markets,\u201d said Kenneth C. Frazier,<br \/>\n      chairman and chief executive officer, Merck. \u201cMerck is about translating<br \/>\n      cutting-edge science into medicines and vaccines that save and improve<br \/>\n      lives throughout the world. By bringing to market new products that make<br \/>\n      a meaningful difference to patients, payers and providers, we\u2019ll<br \/>\n      continue to drive value for our shareholders and society.\u201d\n    <\/p>\n<p>\n      Merck announced in January that it was evaluating strategic options for<br \/>\n      all areas of the business, including Consumer Care and Animal Health, to<br \/>\n      determine whether or not they are core to its strategy. As a result,<br \/>\n      Merck today <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fconsumer-care-news%2Fmerck-announces-sale-consumer-care-business-bayer-ag-142-billion&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=announced+the+sale+of+its+Consumer+Care+business&amp;index=2&amp;md5=28bb326a701e7286fa9bea63c949d26a\" rel=\"nofollow\">announced<br \/>\n      the sale of its Consumer Care business<\/a> to Bayer AG for $14.2 billion<br \/>\n      and entered into a worldwide collaboration with Bayer to market and<br \/>\n      develop a novel portfolio of soluble guanylate cyclase (sGC) modulators<br \/>\n      for the treatment of pulmonary arterial hypertension (PAH) and chronic<br \/>\n      thromboembolic pulmonary hypertension (CTEPH). As part of the<br \/>\n      collaboration, Bayer will receive a $1 billion up-front payment with the<br \/>\n      potential for additional milestone payments upon the achievement of<br \/>\n      agreed-upon sales goals.\n    <\/p>\n<p>\n      During today\u2019s Investor Briefing, Merck said it will continue to explore<br \/>\n      ways to augment its Animal Health business. The company continues to<br \/>\n      view the business as one that will generate long-term shareholder value.\n    <\/p>\n<p>\n      <b>Advancing a Suite of Opportunities<\/b>\n    <\/p>\n<p>\n      Merck\u2019s pipeline contains many promising candidates that represent a<br \/>\n      suite of near- and long-term opportunities that will drive growth and<br \/>\n      shareholder value. The company has prioritized its R&amp;D efforts to focus<br \/>\n      on innovative candidates with meaningful, differentiated attributes. At<br \/>\n      the same time, Merck has increased its commercial focus on key<br \/>\n      therapeutic areas that provide the best opportunities for the business<br \/>\n      and deliver the greatest value for customers, including diabetes, acute<br \/>\n      hospital care, vaccines and oncology.\n    <\/p>\n<p>\n      During the meeting, company executives reaffirmed Merck&#8217;s objective of<br \/>\n      being the premier research-intensive biopharmaceutical company. The<br \/>\n      executives also discussed progress made towards prioritizing the<br \/>\n      company\u2019s R&amp;D portfolio and provided updates on advances in the<br \/>\n      company\u2019s late-stage pipeline and plans for expanding its clinical<br \/>\n      programs to advance its novel candidates in hepatitis C, HIV, diabetes<br \/>\n      and immuno-oncology.\n    <\/p>\n<p>\n      Merck said it also anticipates several regulatory actions and potential<br \/>\n      product launches in 2014 including:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>Launches<\/b><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            GRASTEK (Timothy Grass Pollen Allergen Extract), a sublingual<br \/>\n            allergen immunotherapy tablet for grass pollen-induced allergic<br \/>\n            rhinitis\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            RAGWITEK (Short Ragweed Pollen Allergen Extract), a sublingual<br \/>\n            allergen immunotherapy tablet for ragweed pollen-induced allergic<br \/>\n            rhinitis\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Under Review<\/b><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            MK-3475, an investigational anti-PD-1 antibody for advanced<br \/>\n            melanoma\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Suvorexant, an investigational orexin inhibitor for the treatment<br \/>\n            of insomnia\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            ZONTIVITY (vorapaxar), an investigational, novel PAR-1 antagonist<br \/>\n            for reduction of atherothrombotic events in patients with a prior<br \/>\n            heart attack or with peripheral arterial disease and no history of<br \/>\n            stroke or transient ischemic attack\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            V503, an investigational 9-valent HPV vaccine\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Vaniprevir, an investigational, novel protease inhibitor for the<br \/>\n            treatment of hepatitis C (under review in Japan)\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>Filings Anticipated in 2014<\/b><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Sugammadex, an investigational medicine for the reversal of<br \/>\n            neuromuscular blockade\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Odanacatib, an investigational, novel cathespin K inhibitor for<br \/>\n            the treatment of osteoporosis\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n      The company confirmed plans to submit a New Drug Application (NDA) for<br \/>\n      odanacatib in the second half of 2014 and said that data from its large<br \/>\n      fracture outcomes study have been submitted for presentation at a<br \/>\n      medical meeting later this year. In the Phase 3 fracture study,<br \/>\n      odanacatib substantially reduced the risk of osteoporotic fractures vs.<br \/>\n      placebo, including vertebral, non-vertebral and hip fractures, and the<br \/>\n      risk reduction was robust and sustained. Adverse experiences were<br \/>\n      generally balanced between the odanacatib and placebo groups. Among<br \/>\n      adjudicated adverse effects associated with odanacatib, morphea (areas<br \/>\n      of skin thickening with itching) was reported uncommonly (&lt;0.2%), with<br \/>\n      improvement after discontinuation of treatment, and femoral shaft<br \/>\n      fractures of an atypical type were rare (&lt;0.1%). Both were higher than<br \/>\n      placebo. There were no reported cases of osteonecrosis of the jaw.<br \/>\n      Numerical imbalances were also seen for adjudicated atrial fibrillation<br \/>\n      and strokes, though major cardiovascular events were balanced overall.\n    <\/p>\n<p>\n      Additional late-stage pipeline opportunities where Merck has a legacy of<br \/>\n      leadership and an established global presence were also discussed:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In hepatitis C, the company has initiated Phase 3 trials for<br \/>\n        MK-5172\/MK-8742, its all-oral combination regimen, and also plans to<br \/>\n        initiate studies in combination with sofosbuvir for evaluating shorter<br \/>\n        durations of therapy.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In HIV, the company plans to commence a Phase 3 trial in the fourth<br \/>\n        quarter of 2014 for its non-nucleoside reverse transcriptase<br \/>\n        inhibitor, doravirine (MK-1439), and for raltegravir once-daily, a new<br \/>\n        formulation of its integrase inhibitor ISENTRESS.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In diabetes, the company plans to file omarigliptin, a once-weekly<br \/>\n        DPP-4 inhibitor, in Japan by the end of 2014. In addition, in<br \/>\n        collaboration with Pfizer, Merck continues to evaluate ertugliflozin,<br \/>\n        an investigational oral sodium glucose cotransporter (SGLT2)<br \/>\n        inhibitor, in Phase 3 trials.\n      <\/li>\n<\/ul>\n<p>\n      <b>Delivering in Immuno-oncology<\/b>\n    <\/p>\n<p>\n      Merck is investing to be a leader in oncology and is focused on<br \/>\n      advancing MK-3475. The company <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmerck-announces-fda-acceptance-review-mk-3475-biologics-license-appli&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=announced+that+the+FDA+has+accepted+its+Biologics+License+Application+%28BLA%29+for+MK-3475&amp;index=3&amp;md5=132ec662154bf962b30c755560ba1ea3\" rel=\"nofollow\">announced<br \/>\n      that the FDA has accepted its Biologics License Application (BLA) for<br \/>\n      MK-3475<\/a> for the treatment of advanced melanoma in patients<br \/>\n      previously treated with ipilimumab and granted priority review status.<br \/>\n      The PDUFA date for the BLA is October 28, 2014.\n    <\/p>\n<p>\n      <b>Conference and Webcast Information<\/b>\n    <\/p>\n<p>\n      There will be a live webcast of the event available on Merck&#8217;s website<br \/>\n      at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=61812d4072c853e48e46d1f131d08f00\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      starting at 9:00 a.m. EDT. Software needed to listen to the webcast may<br \/>\n      be obtained on the corporate website and should be downloaded prior to<br \/>\n      the beginning of the webcast. A replay of the webcast will be available<br \/>\n      by the end of the day on May 6, 2014. Institutional investors, analysts<br \/>\n      and members of the media also can participate in the event by dialing<br \/>\n      (706) 634-2289 or (877) 214-9289 and using ID code number 42688075.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=3fa0fac8137db505133781cfe3d29597\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2Fmerck&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=bf688e7c547540295836ac81df6bd0aa\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=e844d243d8fb8170b35992e9f8ff8135\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=96c41644e871649975c3ea85a05e9eee\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50858626&amp;newsitemid=20140506006179&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=f7f54eaa2dd55970b5b79dbd030a9b03\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Steve Cragle, 908-423-3461<br \/>Ian McConnell        908-423-3046<br \/>Investor:<br \/>Joe Romanelli, 908-423-5185<br \/>Carol        Ferguson, 908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014 Provided Updates on Clinical Development Programs for Oncology, Hepatitis C and HIV Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the company\u2019s research facility in Boston. The briefing is also available via webcast at vip2-msd.com\/merckcom-migrated starting at 9:00 a.m. EDT. Members of the company\u2019s senior management team provided updates on the progress Merck has made on its multi-year, strategic initiative to sharpen its commercial and research and development (R&amp;D) focus, bolster its<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744989","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&amp;D Focus; Drive Growth and Productivity - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&amp;D Focus; Drive Growth and Productivity - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014 Provided Updates on Clinical Development Programs for Oncology, Hepatitis C and HIV Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the company\u2019s research facility in Boston. The briefing is also available via webcast at vip2-msd.com\/merckcom-migrated starting at 9:00 a.m. EDT. Members of the company\u2019s senior management team provided updates on the progress Merck has made on its multi-year, strategic initiative to sharpen its commercial and research and development (R&amp;D) focus, bolster its\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/\",\"name\":\"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2014-05-06T07:59:00+00:00\",\"dateModified\":\"2023-03-22T04:04:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&#038;D Focus; Drive Growth and Productivity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/","og_locale":"en_US","og_type":"article","og_title":"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity - Merck.com","og_description":"Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014 Provided Updates on Clinical Development Programs for Oncology, Hepatitis C and HIV Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the company\u2019s research facility in Boston. The briefing is also available via webcast at vip2-msd.com\/merckcom-migrated starting at 9:00 a.m. EDT. Members of the company\u2019s senior management team provided updates on the progress Merck has made on its multi-year, strategic initiative to sharpen its commercial and research and development (R&amp;D) focus, bolster its","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:55+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/","name":"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2014-05-06T07:59:00+00:00","dateModified":"2023-03-22T04:04:55+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506006179r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-highlights-progress-on-its-strategic-initiative-to-sharpen-commercial-and-rd-focus-drive-growth-and-productivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&#038;D Focus; Drive Growth and Productivity"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3502b093-e26d-4864-8eee-e14bc0f52f66","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Highlights-Progress-on-Its-Strategic-Initiative-to-Sharpen-Commercial-and-RD-Focus-Drive-Growth-and-Productivity-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744989\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744989"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}